Siglec-9[Biotin], His & Avi, Human

Siglec-9[Biotin], His & Avi, Human

Siglec-9 is a sialic-acid-binding lectin expressed predominantly on myeloid cells. Aberrant glycosylation occurs in essentially all types of cancers and results in increased sialylation. Thus, when the mucin MUC1 is expressed on cancer cells, it is decorated by multiple short, sialylated O-linked glycans (MUC1-ST).
Z04602
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Siglec-9 (Gln18-Gly348)
Accession # Q9Y336-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 38.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 25mM MES, 150mM NaCl (pH 5.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 25mM MES, 150mM NaCl (pH 5.5).
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Siglec-9 is a sialic-acid-binding lectin expressed predominantly on myeloid cells. Aberrant glycosylation occurs in essentially all types of cancers and results in increased sialylation. Thus, when the mucin MUC1 is expressed on cancer cells, it is decorated by multiple short, sialylated O-linked glycans (MUC1-ST).
Synonyms CD329; CDw329; FOAP-9; OBBP-Like; Siglec-9; SIGLEC9

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.